Latest Compass Pathways News & Updates

See the latest news and media coverage for Compass. We track all announcements, press releases, and industry mentions in real time, all in one place.

Compass Pathways (Compass)

Mental health biotechnology company

compasspathways.com

Headquarters: London, United Kingdom
Founded year: 2016
Company type: Public company
Number of employees: 200–320
Industry: Pharmaceuticals

Last updated October 27

Latest news about Compass Pathways (Compass)

In short: Compass reported positive Phase 3 data and advanced COMP360 toward a 2027 launch.

Company announcements

October 27 Compass

Compass announces Q3 2026 earnings call

The company will release results and provide a business update on November 3, 2026. A live webcast is available for investors.

September 30 Compass

Compass Pathways appoints Kelley Boucher as Chief People Officer

Ms. Boucher joins to lead people strategy and prepare the executive team for COMP360 psilocybin launch in 2027.

September 10 Compass

Compass awards grants for COMP360 provider training

Five organizations selected to develop training for healthcare providers preparing for the potential commercial launch of the psychedelic treatment.

September 9 Compass

Compass reports positive 52-week COMP360 trial data

Results show sustained durability and strong response rates for treatment-resistant depression, supporting the NDA submission in Q4 with a targeted launch in H1 2027.

Media coverage

October 25 Business Insider

After a long, strange trip, this CEO is close to taking a psilocybin pill to market

Compass Pathways is on the cusp of FDA approval for a proprietary version of psilocybin — the active drug in magic mushrooms.

October 18 Simply Wall St

COMPASS Pathways (CMPS) Reports Positive Phase 3 Data, Is The Premium Still Justified? - Simply Wall St News

Still, the whole COMPASS Pathways story hinges on clean Phase 3 outcomes and efficient cash use, so any trial setback or funding need could quickly...

September 22 Yahoo Finance

Compass Pathways Eyes 2027 COMP360 Launch as FDA Filing Nears

Compass Pathways (NASDAQ:CMPS) said it expects to complete its rolling New Drug Application submission for its synthetic psilocybin treatment, COMP360, in the fourth quarter and...

September 20 Psychiatric Times

COMP360 for Treatment-Resistant Depression: Insights on New Phase 3 Trials From Guy Goodwin, MD | Psychiatric Times

Compass Pathways reports COMP360 psilocybin shows fast, durable relief in treatment‑resistant depres...

Never miss news about Compass

Track Compass and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Compass competitors & trending companies

Browse news for competitors to Compass and other trending companies.